Javascript must be enabled to use this form.

View Profile	Home Browse Faculty Facility Research Consortia Training Grants Courses Search Support About rSp Help and FAQ's Contact Us	GCC Home
Faculty Profile Last Modified Time: 05:06:44 PM Thu, 11 Jul 2024   Contact Information Dung-Fang Lee Associated Profiles  Associate Professor, Integrative Biology and Pharmacology, UT Health Science Center at Houston   Medical School Building, Room No.: 4.110    Dung-Fang.Lee@uth.tmc.edu     (713)500-6132    Web Link    iPSC Disease Modelling, Cancer Pathological Mechanisms, Cancer, Cancer Biology, Tumors, Kinase, Phosphorylation, Signaling Pathways, Tumor Biology, Cancer Cell Biology, Molecular Oncology, Signal Transduction    Associated Profiles Professional Preparation Research and Expertise Affiliations Appointments  Professional Preparation  Degree Major Institution Year  PhD Cancer Biology University of Texas Health Science Center at Houston 2008  Research and Expertise Research Interests   In vitro modeling of human disease has recently become possible due to induced pluripotent stem cell (iPSC) methodologies. Characterized by their ability to self-renew indefinitely and differentiate into all cell lineages of an organism like embryonic stem (ES) cells, iPSCs provide a powerful and unlimited source of cells to generate differentiated cells that can be used to elucidate disease pathogenesis, for drug discovery and development, toxicology screening, personalized healthcare and eventually cell transplantation-based therapies. Our laboratory is dedicated to understand cancer pathological mechanisms by applying pluripotent stem cells (PSCs) including patient-specific iPSCs and engineered ESCs. We have modelled familial cancer disease Li-Fraumeni syndrome (LFS) by using patient-derived iPSCs and delineated the pathological mechanisms caused by mutant p53 in osteosarcoma. Currently we focus on (1) Systems-level analyses and characterization of mutant p53 in LFS-associated osteosarcoma by using osteoblasts derived from genetically TALEN/CRISPR engineered PSCs. (2) Systematic analyses of genome alterations during tumor progression to identify the potential second hit required for osteosarcoma formation. (3) Model other familial cancer syndromes with osteosarcoma predisposition by patient-derived iPSCs to explore the central pathological mechanisms triggering osteosarcoma development.  Publications/Creative Works Click here to search for this faculty member's publications on PubMed.  Affiliations  Research Consortia Junior Faculty Network  Training Grants Training Interdisciplinary Pharmacology Scientists  Appointments Title Department / School Institution Associate Professor Integrative Biology and Pharmacology UT Health Science Center at Houston

powering - The Partnership
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.